All In Biotech

Drug Trial Radar · NCT07185321

A Phase 1 Study of Mosliciguat in Healthy, Adult Males

An Open-Label, Phase 1 Study to Investigate the Absolute Bioavailability and the Absorption, Metabolism, and Excretion of [14C]-Mosliciguat in Healthy, Adult Males

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Jun 10, 2025

Primary completion

Jun 30, 2025

Study completion Jul 13, 2025

Sponsor

Lead sponsor
Pulmovant, Inc.Industry
Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy male adults.

Conditions

  • Healthy Volunteer

Interventions

  • MosliciguatDrug

    Dose level for inhalation

  • 14C mosliciguatDrug

    Dose level

  • Dry Powder InhalerDevice

    Dry powder inhaler for mosliciguat

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the absolute bioavailability (ABA) of mosliciguat following administration of a single inhaled dose of mosliciguat followed by an IV microtracer dose of [14C]-mosliciguat in healthy adult malesTime frame: Baseline, Day 7
  2. Area under the concentration-time curve (AUC) for mosliciguatTime frame: Baseline, Day 7
  3. Assess the mass balance (i.e., cumulative excretion in urine and feces compared to the administered amount of radioactive isotope) of [14C] following a single oral dose of mosliciguat solutionTime frame: Baseline, Day 28
  4. Maximum observed concentration (Cmax)Time frame: Baseline, Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.